UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 591

Sortiert nach

Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years

Diabetes, obesity & metabolism, 2014-02, Vol.16 (2), p.124-136

2014

Volltextzugriff (PDF)

Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin

Diabetes, obesity & metabolism, 2014-02, Vol.16 (2), p.159-169

2014

Volltextzugriff (PDF)

Durability and tolerability of dapagliflozin over 52 weeks as add-on to metformin and sulphonylurea in type 2 diabetes

Diabetes, obesity & metabolism, 2015-11, Vol.17 (11), p.1075-1084

2015

Volltextzugriff (PDF)

Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin

Diabetes, obesity & metabolism, 2012-11, Vol.14 (11), p.990-999

2012

Volltextzugriff (PDF)

Durability of glycaemic efficacy over 2years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin

Diabetes, obesity & metabolism, 2014-11, Vol.16 (11), p.1111-1120

2014

Volltextzugriff (PDF)

Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin

Diabetes, obesity & metabolism, 2014-11, Vol.16 (11), p.1111-1120

2014

Volltextzugriff (PDF)

Dapagliflozin-induced weight loss affects 24-week glycated haemoglobin and blood pressure levels

Diabetes, obesity & metabolism, 2015-08, Vol.17 (8), p.809-812

2015

Volltextzugriff (PDF)

Patient-reported outcomes among patients with type 2 diabetes mellitus treated with dapagliflozin in a triple-therapy regimen for 52weeks

Diabetes, obesity & metabolism, 2016-03, Vol.18 (3), p.306-309

2016

Volltextzugriff (PDF)

Patient-reported outcomes among patients with type 2 diabetes mellitus treated with dapagliflozin in a triple-therapy regimen for 52 weeks

Diabetes, obesity & metabolism, 2016-03, Vol.18 (3), p.306-309

2016

Volltextzugriff (PDF)

Effects of silage type and inclusion level on ruminal characteristics and feeding behavior of steers fed finishing diets

Journal of animal science, 2017-10, Vol.95 (10), p.4623-4637

2017

Volltextzugriff (PDF)

Health-related quality of life (EQ-5D) among type 2 diabetes mellitus patients treated with dapagliflozin over 2 years

International journal of clinical practice (Esher), 2014-04, Vol.68 (4), p.486-494

2014

Volltextzugriff (PDF)

Change in quality of life (EQ-5D) among type 2 diabetes mellitus patients inadequately controlled with metformin plus sulfonylurea and treated with dapagliflozin as triple therapy regimen for 24 weeks

Value in health, 2014-05, Vol.17 (3), p.A257-A257

2014

Volltextzugriff (PDF)

Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin

The journal of clinical endocrinology and metabolism, 2012-03, Vol.97 (3), p.1020-1031

2012

Volltextzugriff (PDF)

Risk factors for Helicobacter pylori resistance in the United States: the surveillance of H. pylori antimicrobial resistance partnership (SHARP) study, 1993-1999

Annals of internal medicine, 2002-01, Vol.136 (1), p.13

2002

Volltextzugriff (PDF)

A Pharmacokinetic and Pharmacodynamic Comparison of Immediate-Release Metoprolol and Extended-Release Metoprolol CR/XL in Patients with Suspected Acute Myocardial Infarction: A Randomized, Open-Label Study

Cardiology, 2014-01, Vol.127 (2), p.73-82

2014

Volltextzugriff (PDF)

Finite-element models for open-air power lines in broadband PLC

IEEE transactions on power delivery, 2006-10, Vol.21 (4), p.1898-1904

2006

Volltextzugriff (PDF)

Association of local progression with deterioration of urinary symptoms and occurrence of genitourinary adverse events (AEs) in nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC): Post hoc analysis of PROSPER

European urology, 2021-06, Vol.79, p.S1738-S1739

2021

Volltextzugriff (PDF)

Time Course of Inhibition in Color-Response and Word-Response Versions of the Stroop Task

Journal of experimental psychology. Human perception and performance, 1994-06, Vol.20 (3), p.647-675

1994

Volltextzugriff (PDF)

691TiP A phase III, randomized study of enzalutamide (ENZA) plus leuprolide (LHRHa), ENZA monotherapy, and placebo plus LHRHa in men with high-risk nonmetastatic hormone-sensitive prostate cancer (nmHSPC) progressing after local therapy: EMBARK final protocol/study status

Annals of oncology, 2020-09, Vol.31, p.S547-S547

2020

Volltextzugriff (PDF)

P300 from auditory stimuli: intensity and frequency effects

Biological psychology, 1995-11, Vol.41 (3), p.255-269

1995

Volltextzugriff (PDF)

685P A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic castration-resistant prostate cancer (nmCRPC): Outcomes by prostate-specific antigen (PSA) response

Annals of oncology, 2020-09, Vol.31, p.S544-S545

2020

Volltextzugriff (PDF)

275 Assessment of Eragrostis tef (Zucc.) as a forage base for growing beef steers

Journal of animal science, 2017-08, Vol.95 (suppl_4), p.136-136

2017

Volltextzugriff (PDF)

Assessment of Eragrostis tef (Zucc.) as a forage base for growing beef steers

Journal of animal science, 2017-08, Vol.95, p.136

2017

Volltextzugriff (PDF)

635P ARCHES - The role of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): Post hoc analyses of efficacy by baseline prostate-specific antigen (PSA) levels

Annals of oncology, 2020-09, Vol.31, p.S523-S524

2020

Volltextzugriff (PDF)

Effect of Helicobacter pylori eradication on development of erosive esophagitis and gastroesophageal reflux disease symptoms: A post hoc analysis of eight double blind prospective studies

The American journal of gastroenterology, 2002-12, Vol.97 (12), p.2992-2997

2002

Volltextzugriff (PDF)

1 – 25 von 591

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(507)
Mit Volltextzugriff
(507)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(339)
Life Sciences & Biomedicine
(296)
Humans
(231)
Female
(153)
Middle Aged
(128)
Male
(124)
Adult
(101)
Aged
(89)
Biological And Medical Sciences
(85)
Surgery
(80)
Animals
(73)
Medical Sciences
(64)
Oncology
(47)
Physical Sciences
(40)
Adolescent
(39)
Physics
(39)
Exact Sciences And Technology
(37)
Public, Environmental & Occupational Health
(37)
General & Internal Medicine
(33)
Breast Cancer
(31)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years

Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin

Durability and tolerability of dapagliflozin over 52 weeks as add-on to metformin and sulphonylurea in type 2 diabetes

Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin

Durability of glycaemic efficacy over 2years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin

Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin

Dapagliflozin-induced weight loss affects 24-week glycated haemoglobin and blood pressure levels

Patient-reported outcomes among patients with type 2 diabetes mellitus treated with dapagliflozin in a triple-therapy regimen for 52weeks

Patient-reported outcomes among patients with type 2 diabetes mellitus treated with dapagliflozin in a triple-therapy regimen for 52 weeks

Effects of silage type and inclusion level on ruminal characteristics and feeding behavior of steers fed finishing diets

Health-related quality of life (EQ-5D) among type 2 diabetes mellitus patients treated with dapagliflozin over 2 years

Change in quality of life (EQ-5D) among type 2 diabetes mellitus patients inadequately controlled with metformin plus sulfonylurea and treated with dapagliflozin as triple therapy regimen for 24 weeks

Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin

Risk factors for Helicobacter pylori resistance in the United States: the surveillance of H. pylori antimicrobial resistance partnership (SHARP) study, 1993-1999

A Pharmacokinetic and Pharmacodynamic Comparison of Immediate-Release Metoprolol and Extended-Release Metoprolol CR/XL in Patients with Suspected Acute Myocardial Infarction: A Randomized, Open-Label Study

Finite-element models for open-air power lines in broadband PLC

Association of local progression with deterioration of urinary symptoms and occurrence of genitourinary adverse events (AEs) in nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC): Post hoc analysis of PROSPER

Time Course of Inhibition in Color-Response and Word-Response Versions of the Stroop Task

691TiP A phase III, randomized study of enzalutamide (ENZA) plus leuprolide (LHRHa), ENZA monotherapy, and placebo plus LHRHa in men with high-risk nonmetastatic hormone-sensitive prostate cancer (nmHSPC) progressing after local therapy: EMBARK final protocol/study status

P300 from auditory stimuli: intensity and frequency effects

685P A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic castration-resistant prostate cancer (nmCRPC): Outcomes by prostate-specific antigen (PSA) response

275 Assessment of Eragrostis tef (Zucc.) as a forage base for growing beef steers

Assessment of Eragrostis tef (Zucc.) as a forage base for growing beef steers

635P ARCHES - The role of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): Post hoc analyses of efficacy by baseline prostate-specific antigen (PSA) levels

Effect of Helicobacter pylori eradication on development of erosive esophagitis and gastroesophageal reflux disease symptoms: A post hoc analysis of eight double blind prospective studies

Suchergebnisse filtern